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   Despite significant advances in the early diagnosis and treatment of locally advanced breast cancer, 60–65% of 
the Republic of Uzbekistan is accounted for by locally advanced breast cancer and its mortality rate is high. The 
morphological structure of breast cancer is important for the prognosis of the disease. On cell membranes there are special 
cytoplasmic proteins - receptors, which, when combined with hormones, can affect the rate of division of tumor cells. In 
terms of the choice of treatment options and the assessment of the forecast, some molecular genetic parameters of the tumor 
are important, among which, first of all, the hormonal status of the tumor (ER / PR), HER-2 / neu, p53, Bcl-2, Ki-67 . 
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1. Introduction 
 Breast cancer (BC) is still one of the main urgent problems of fundamental and clinical oncology, the intensity of which 
remains the highest among malignant neoplasms in women [1].According to a number of authors, in 2000, the average breast 
cancer incidence in Russia was 19.40%, in Moldova 22.90%, in Belarus 18.30%, in Georgia 36.00%, in Armenia 28.40%, in 
Kazakhstan 18.30%, in Uzbekistan 19.10% and is characterized by high neglect. (3)The incidence of breast cancer in women 
in Western countries is 5 times higher than in women living in Asian countries. In the western population, the incidence of 
breast cancer increases mainly in the postmenopausal age, while in Asian countries it is mainly in women under 50 years old, 
that is, at reproductive age.Despite significant advances in the early diagnosis and treatment of breast cancer, in the Republic 
of Uzbekistan 60-65% is accounted for by locally advanced breast cancer and mortality from it is high and tends to 
constantly increase. The mortality rate of women with this localization of malignant tumor is in third place after diseases 
cardiovascular system and accidents, and in the first place in the structure of female mortality from cancer - 16.4% (5) .In 
this case, the diagnosis is morphologically verified in 90-95% of cases.Stage I-II breast cancer is diagnosed in 60.3% of 
patients, stage III in 26.1% and stage IV in 12.4% of patients. The highest incidence rates are observed in the age groups 60-
64.75 years and older : 134.6 and 137.68 per 100,000 population. (5) 
2. Main part 
 In Uzbekistan, there is an increase in the number of primary breast cancer patients per 100,000 women, which amounted 
to 6.6 in the Republic of Uzbekistan as a whole. In the regions of Uzbekistan, the greatest increase in the incidence rate was 
noted in the Republic of Karakalpakstan - 1.7 times, and in Tashkent city - 1.5 times. Mortality from breast cancer also 
increased from 1985 to 2004, and this increase is greater in Bukhara and Surkhandarya. areas, 3.9; 3.8 times, respectively. 
[4].  The morphological structure of breast cancer is important for prognosis diseases. Invasive ductal carcinoma is most 
common up to 80%. Special forms of invasive cancer, starting with lobular and lower, generally have a less malignant course 
than invasive ductal carcinoma, and therefore at one time were singled out into a special group.They make up about 15–20% 
of all neoplasms. Tumors of mixed histological structure are quite common. In such cases, predominance of some type of 
cancer is noted.On cell membranes there are special cytoplasmic proteins - receptors, which, when combined with hormones, 
can affect the rate of division of tumor cells. Determination of the level of steroid hormone receptors (estrogens, 
progesterone, etc.) makes it possible to predict the course of the disease and to judge the sensitivity of the tumor to hormonal 
treatment.Locally advanced breast cancer differs from localized not only in the degree of tumor prevalence; in this variant, 
the frequency of tumors with a poor prognosis increases and the frequency of relatively favorable characteristics 
decreases.So, according to the Russian Oncology Center.N.N.Blokhin Russian Academy of Medical Sciences, the frequency 
of rare morphological forms of cancer with a relatively benign course (mucous, papillary, tubular and medullary) in early 
breast cancer (T1-2N0M0) is 11%, and in MR BC - 2%. Aneuploid tumors in early breast cancer were observed in 62%, and 
in MR breast cancer - in 85%, and the proportion of aneuploid-polyclonal neoplasms was 4% and 17%, respectively [6]. 
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According to some reports, in the case of the Infiltrative Form, the frequency of tumors with overexpression of HER2 neu 
increases to 40-50%.  
  Among the huge number of molecular biological studies related to the prediction of breast cancer and the search for 
factors predicting the sensitivity of the tumor to various methods of treatment, one should include an integral assessment of a 
huge number of molecular biological characteristics of neoplasms, which is represented by the classification of breast cancer, 
based on variations in the set of expressed genes and the correlation of genetic characteristics of the tumor with long-term 
results.These characteristics also allow individualizing treatment and thereby improve its results [6,14]. In terms of choosing 
a treatment option and assessing prognosis, some molecular genetic parameters of the tumor are important, among which, 
first of all, the hormonal status of the tumor (ER / PR), HER-2 / neu, p53, Bcl-2, Ki-67 Surrogate isolation of the proposed 
BC subtypes has come into practice, based on the immunohistochemical study of ER, RP and HER2neu: the luminal type is 
characterized as ER + HER2neu-, HER2neu + subtype - any values of ER and RP with overexpression of HER2neu. basal 
subtype - RE-RP-HER2neu. Revision of the results of systemic therapy depending on the tumor subtype showed the 
predictive value of the new classification. Investigation of the ER / PR-status of breast cancer cells is performed by the 
immunohistochemical method in order to determine the indications for hormone therapy [17]. At the same time, 
immunohistochemistry helps in the choice of treatment for Neoadjuvant Poly Chemotherapy. Thus, with the neoadjuvant use 
of anthracyclines and taxanes in patients with breast cancer with ER (-), complete or partial morphological regression is 
more often recorded [13]. Interesting and conflicting results of studies on changes in the hormonal status of a tumor under 
the influence of chemotherapy.So LeeS.H.et al. [16] showed that the ER / PR status changes in 62% of cases after 
Neoadjuvant Poly Chemotherapy. On the contrary, Arens N. et al. [8] did not describe changes in ER / PR before and after 
treatment, while Kasami M. et al. [9] found changes only in the expression of progesterone receptors in the tumor under the 
influence of Neoadjuvant Poly Chemotherapy. It is known that epidermal growth factor, represented by the family of 
tyrosine kinase receptors, is involved in the regulation of breast cancer cell proliferation, among which the HER-2 / 
neuoncogene should be distinguished [10]. When HER-2 / neu is overexpressed, conditions are created for the activation of 
uncontrolled cell division processes, which is closely related to accelerated tumor growth and a tendency to invasive growth, 
early metastasis, high risk of recurrence, shortening of the overall and disease-free survival rates and indicates an aggressive 
course of the disease [12 ]. That is why current standards recommend evaluating HER-2 / neu, the level of which can be high 
both in the primary tumor and in lymphogenous metastases [11]. 
  The most important indicator of the biological behavior of a malignant tumor is also the proliferative activity of its 
cellular elements. The size of the proliferative pool of tumor cells is assessed by the immunohistochemical method according 
to the proliferation marker, the K1-67 antigen. [2] It was found that a positive reaction to this antigen clearly correlates with 
the degree of tumor malignancy and has an inverse relationship with the level of estrogen and progesterone receptors, and is 
also a predictive factor for chemoradiation therapy [15]. 
  Concluding, we can say that MR breast cancer is a systemic disease, the success of its treatment is associated with 
the progress of systemic therapy. The observed low efficiency of preoperative therapy (the presence of a residual tumor in 
70-90% of cases) requires surgery and radiation therapy. An increase in the effectiveness of treatment in general has been 
proven when taxanes and capecitabine are included in the chemotherapy regimen, and trastuzumab for patients with 
HER2neu overexpression. [6,7] The molecular characteristics of the tumor increase the possibilities of individualization of 
treatment. In-depth study of the problem Locally advanced breast cancer makes it possible to expand the scientific 
understanding of the mechanism of carcinogenesis, to develop optimal approaches to improving the prevention, diagnosis 
and treatment of malignant neoplasms. 
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